Sensenbrenner Clinical Study

Sensenbrenner Syndrome Clinical Trial

— Sensenbrenner  

Official title:

An Observational, Clinical Study to Collect the Medical Data in Order to Determine the Craniofacial Characteristics Through Phenotypic Analysis on Children With Sensenbrenner Treated/Followed at the Hôpital Femme Mère Enfant From 2005

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04184531
• Other study ID #: Sensenbrenner_2019
• Status: Not yet recruiting
• Start date: January 2020
• Est. completion date: July 2020

Study information

• Verified date: November 2019
• Source: Hospices Civils de Lyon
• Contact: Federico DI ROCCO, Pr
• Phone: 4 72 35 75 72
• Email: federico.dirocco[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sensenbrenner syndrome, also known as cranioectodermal dysplasia (CED), is a rare autosomal-recessive disorder belonging to the ciliopathy group of diseases. It is characterized by a facial dysmorphism, abnormal bone development and ectodermal defects including dental anomalies. CED is a heterogeneous condition with significant phenotypic and molecular variability, whose spectrum may include cases of renal impairment, hepatic fibrosis, retinitis pigmentosa and/or brain anomalies. In many cases, patients develop chronic kidney disease (CKD) due to nephronophthisis between 2 and 6 years of age. The aim of this retrospective study is to better understand the characteristics of this syndrome and to find prognostic factors of CKD. We make the hypothesis that an early diagnosis of the syndrome would lead to a better global management of patients (quality of life, delayed onset of end-stage renal disease).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 4
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 13 Years

Eligibility

Inclusion Criteria:

• Boys and girls.

• Aged 3 to 18 years old.

• Subjects with a Sensenbrenner's syndrome diagnosis and followed from 2005

• Parents/ legal guardian must provide non opposition prior to participation in the study

Exclusion Criteria:

• Patients whose parents / legal guardian have object to using the data usually collected for care

Related Conditions & MeSH terms

• Sensenbrenner Syndrome

Intervention

Other:
• Medical Data Collect
It is a retrospective clinical study and we will collect only the medical data registered in our hospital software

Locations

Country	Name	City	State
France	Hôpital Femme-Mère-Enfant	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of renal impairment of 4 patients with Sensenbrenner identified with WDR19 and WDR35 mutations, through measurement of level of creatinine in the urine.	In many cases, patients with this syndrome develop chronic kidney disease (CKD) due to nephronophthisis between 2 and 6 years of age. Nephronophthisis is characterized by decreased urine concentration ability, chronic tubulointerstitial nephritis, cystic kidney disease and progression towards end-stage kidney disease (ESKD). In this study, we would analyze the renal phenotypes through the level of Creatinine in the urine to detect early-stage kidney disease. All the data will be collected from the patient medical records.	The result of Creatinine in children with Sensenbrenner syndrome will be collected though study completion an average of 1 year.